


**[ATS] Do Inhaled
Corticosteroids (ICS)
Reduce Rate Of Decline Of
Lung Function In
COPD Patients With
Eosinophil Count \geq 2%?**

Barnes N, Sharma R, Lettis S,
Calverley PM

EPOC AVANCES

ERS ATS


SEPAR



Background and objectives



- COPD patients with a blood eosinophil count ≥ 2 % show a greater reduction in exacerbations when given ICS.



Pascoe et al. Lancet Resp Med 2015

- Whether the same is true for rate of decline of lung function is unknown.

Methods




- The results of ISOLDE (FLTB3054) (Burge PS et al BMJ 2000;320:1297–303), a 3-year study of the effects of FP 500mcg twice daily on rate of decline of FEV₁ in well-characterised COPD patients were re-analysed by baseline blood eosinophil count ($\geq 2\%$, $< 2\%$).

Results



- Eosinophil count was $<2\%$ in 68% of patients; the spirometric characteristics of these patients were similar to those with an eosinophil count $\geq 2\%$.

Blood eosinophil count and rate of decline of FEV₁ in response to treatment with FP or placebo




Discussion



- A baseline blood eosinophil count of $\geq 2\%$ identifies a group of COPD patients who show a slower rate of decline of FEV₁ when treated with ICSs.

[Original Research]

CHEST



Rationale for the Dutch Hypothesis*
 Allergy and Airway Hyperresponsiveness as
 Genetic Factors and Their Interaction With
 Environment in the Development of Asthma and
 COPD

Dirkje S. Postmus, MD, PhD, and H. Marike Beenen, PhD

Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort

Borja G. Cosío, MD; Joan B. Soriano, MD; José Luis López-Campos, MD; Myriam Calle-Rubio, MD;
 Juan José Soler-Cataluna, MD; Juan P. de-Torres, MD; José M^a Marin, MD; Cristina Martínez-González, MD;
 Pilar de Lucas, MD; Isabel Mir, MD; Germán Pece-Barba, MD; Nuria Feu-Collado, MD; Ingrid Solanes, MD;
 Inmaculada Alfageme, MD; and Ciro Casanova, MD; on behalf of the CHAIN Study

